Pune, Nov 2026 : Maharashtra Food and Drug Administration (FDA) Minister Narhari Zirwal has reportedly stayed action initiated by FDA Commissioner Tukaram Mundhe against a methanol manufacturing company in Ranjangaon, Pune district, prompting questions about the reasons behind the intervention.
The FDA had initiated proceedings against the company following a toxic liquor tragedy in Pune, in which several people reportedly died. The action, taken under Mundhe’s leadership, was part of efforts to prevent the misuse of methanol and curb the sale of adulterated food and other products.
The minister’s subsequent decision to stay the action has raised concerns about possible interference in the department’s enforcement measures.
Allegations have also emerged that the company is linked to a Nationalist Congress Party (NCP) leader and that political pressure may have influenced the decision. However, these claims have not been independently established.
Mundhe has drawn attention since taking charge of the FDA for his strict enforcement approach. The department has reportedly intensified inspections and action against companies and establishments following complaints, regardless of their size or influence.
The enforcement drive has received appreciation from members of the public, particularly for steps aimed at curbing food adulteration. It has also brought increased scrutiny to the use of artificial colours in food products, including jaggery and jalebis.
There had been speculation that Mundhe would be transferred from the FDA to Rajasthan. He dismissed the reports, stating that he could not be transferred outside Maharashtra.
Reports have cited a 557 per cent increase in complaints received by the FDA since Mundhe took charge. The rise has been attributed to greater public awareness and the department’s intensified enforcement efforts.
The stay on the action against the Ranjangaon-based company has now brought the FDA’s proceedings into focus. Questions remain over the circumstances surrounding the minister’s intervention and whether the department will resume action against the firm.
The developments have also renewed attention on the balance between regulatory enforcement and political oversight, as the FDA continues its efforts to address adulteration and the misuse of industrial chemicals.
